Erythropoietin Alfa

Epocrit is an erythropoiesis-stimulating agent (ESA) indicated for:
Treatment of anemia due to:
Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis.
Zidovudine in HIV-infected patients.
The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy.
... Read more
Epocrit is an erythropoiesis-stimulating agent (ESA) indicated for:
Treatment of anemia due to:
Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis.
Zidovudine in HIV-infected patients.
The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy.
Reduction of allogeneic RBC transfusions in patients undergoing elective, noncardiac, nonvascular surgery.
Prevention of anemia of prematurity in infants with a birth weight of 750 to 1500 gm and gestational age of less than 34 weeks.

Adverse reactions in 5% of Epocrit treated patients in clinical studies were:
Patients with CKD: Hypertension, arthralgia, muscle spasm, pyrexia, dizziness, medical device malfunction, vascular occlusion, and upper respiratory tract infection.
Zidovudine-treated HIV-infected Patients: Pyrexia, cough, rash, and injection site irritation.
Cancer Patients on Chemotherapy: Nausea, vomiting, myalgia, arthralgia, stomatitis, cough, weight decrease, leukopenia, bone pain, rash, hyperglycemia, headache, depression, dysphagia, hypokalemia, and thrombosis.
Surgery Patients: Nausea, vomiting, pruritus, headache, injection site pain, chills, deep vein thrombosis, cough, and hypertension.
Premature infants: A fall in serum ferritin values is very common (>10%)